Case Western Reserve University-ko ikertzaileekin lankidetzan egindako argitalpenak (27)

2022

  1. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19

    The Lancet Oncology, Vol. 23, Núm. 7, pp. e334-e347

  2. Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma

    Clinical Genitourinary Cancer, Vol. 20, Núm. 5, pp. e440-e452

  3. Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer

    BJU International, Vol. 130, Núm. 5, pp. 592-603

  4. Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma

    Clinical Genitourinary Cancer, Vol. 20, Núm. 6, pp. 558-567

  5. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

    Journal of Clinical Oncology, Vol. 32

  6. RESILIENT part 1: a phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer

    Cancer, Vol. 128, Núm. 9, pp. 1801-1811

  7. Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin

    Clinical Genitourinary Cancer, Vol. 20, Núm. 2, pp. 165-175

2021

  1. A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors

    European urology oncology, Vol. 4, Núm. 3, pp. 464-472

  2. Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes

    BJU International, Vol. 128, Núm. 2, pp. 196-205

  3. Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer

    Human Genetics and Genomics Advances, Vol. 2, Núm. 3

  4. Quantifying duration of proteinuria remission and association with clinical outcome in IgA nephropathy

    Journal of the American Society of Nephrology, Vol. 32, Núm. 2

  5. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. Pediatric NMOSD: A Review and Position Statement on Approach to Work-Up and Diagnosis

    Frontiers in Pediatrics, Vol. 8

2019

  1. Genome-wide association study of germline variants and breast cancer-specific mortality

    British Journal of Cancer, Vol. 120, Núm. 6, pp. 647-657

  2. Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes

    American Journal of Human Genetics, Vol. 104, Núm. 1, pp. 21-34

  3. Publisher Correction: Shared heritability and functional enrichment across six solid cancers (Nature Communications, (2019), 10, 1, (431), 10.1038/s41467-018-08054-4)

    Nature Communications

  4. Shared heritability and functional enrichment across six solid cancers

    Nature Communications, Vol. 10, Núm. 1

2018

  1. Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group

    European Journal of Cancer, Vol. 100, pp. 35-45

  2. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors)

    Clinical Microbiology and Infection, Vol. 24, pp. S21-S40

2017

  1. Association analysis identifies 65 new breast cancer risk loci

    Nature, Vol. 551, Núm. 7678, pp. 92-94